This protocol outlines the steps required to perform ex vivo validation of in vivo near-infrared fluorescence (NIRF) xenograft imaging experiments in mice using fluorophore labelled nanobodies and conventional antibodies.
Introduction
In the present report, we describe the implementation of near-infrared fluorophore labelled probes for validation of in vivo xenograft imaging experiments by using ex vivo flow cytometry and fluorescence microscopy of the dissected xenograft tumors. We compare a single domain nanobody (s+16a, 17 kDa) 1 and a monoclonal antibody (Nika102, 150 kDa) 2, 3 directed to the same target antigen for specific in vivo nearinfrared fluorescence imaging in a lymphoma xenograft model. The target antigen ADP-ribosyltransferase ARTC2.2 is expressed as a GPIanchored cell surface ecto-enzyme by lymphoma cells [4] [5] [6] [7] [8] [9] .
Nanobodies derived from camelid heavy-chain-only antibodies are the smallest available antigen-binding fragments 10, 11 . With only ~15 kDa, these small antibody fragments are soluble, very stable and are renally cleared from circulation 8, 10 . These properties make them particularly suited for specific and efficient targeting of tumor antigens in vivo [12] [13] [14] [15] [16] [17] [18] [19] [20] . Common antigen targets of available nanobodies are the epidermal growth factor receptor (EGFR1 or HER-1), human epidermal growth factor type 2 (HER-2 or CD340), carcinoembryonic antigen (CEA) and vascular cell adhesion molecule-1 (VCAM-1) 21 . Nanobody conjugates are promising tools for cancer immunotherapy and treatment of inflammatory diseases 22 .
Recent studies have shown that nanobodies allow higher tumor-to-background (T/B)-ratios than conventional antibodies in in vivo molecular imaging applications 8, 17, 19 1. Preparation of Lymphoma Cells and Aliquoting of Basement Matrix (Matrigel).
1. The day before injection of tumor cells put a sterilized tip box (1,000 µl tips) and the appropriate pipette in -20 °C freezer. 2. Thaw the bottle with the basement matrix on ice in the 4 °C fridge O/N. 3. On the day of injection fill an ice bucket and place the basement matrix along with pipette, tips, and 1 ml syringes with 30 G needles on ice. 4. Aliquot lymphoma cells in a volume of 100 µl of RPMI medium in 1.5 ml microcentrifuge tubes and mix carefully with 100 µl of the basement matrix. Draw up into pre-cooled syringes and put on ice until injection. NOTE: Use good sterile technique and to work on ice the whole time to prevent clogging of the basement matrix.
Mice Preparation 1. Use 8-10 week old athymic nude mice (NMRI-Foxn1 nu
). 2. To reduce autofluorescence of the intestine keep mice on an alfalfa-free diet for 1 week prior to in vivo imaging. 3. For injection of lymphoma cells anesthetize mice to effect with 2% isoflurane in an induction chamber. Maintain 1-2% isoflurane for the duration of the procedure using an isofluorane manifold. 4. Inject lymphoma cells subcutaneously into the shoulder flanks. For direct intra-individual comparison inject antigen-positive and antigen-negative cells on the right and left side, respectively. 1. Use a thumb and index finger to pinch the skin of the mouse and pull it away from the body of the mouse. Inject slowly and evenly into the pouch created by the fingers, creating a single cluster of cells beneath the skin. The basement matrix helps keeping injected cells in place. 
Preparation of

In Vivo Imaging
1. After 7-9 days, when tumors reach ~8 mm in diameter, inject 50 µg of AlexaFluor680 labelled antibody constructs in a volume of 200 µl saline intravenously into the tail vein of the mouse (mAb-AF680: 50 µg with 2 dyes/molecule ≈ ~4^14 fluorochromes ≈ ~0.8 µg fluorochromes; Nanobody-AF680: 50 µg with 0.3 dyes/molecule ≈ ~5.6^14 fluorochromes ≈ ~1.1 µg fluorochromes). 2. Initialize the imaging system and anesthetize mice to effect with 3% isoflurane using an XGI-8 anesthesia system in the induction chamber prior to imaging. Maintain 1-2% isoflurane for the duration of the imaging procedure using the isoflurane manifold housed in the imaging chamber. 3. Choose fluorescent filter sets of 615-665 nm for excitation, 695-770 nm for emission, and 580-610 nm excitation for background subtraction with a 51 2x 512 pixel matrix size. Set exposure time to auto, pixel binning to medium and F/Stop to 2. NOTE: Shorter exposure times enable faster frame rates; longer exposure times provide greater sensitivity. Binning controls the pixel size on the CCD camera. Increasing the binning increases the pixel size, sensitivity, and frame rate, but reduces spatial resolution. F/Stop sets the size of the camera lens aperture. The aperture size controls the amount of light detected and the depth of field.Note that settings can differ by imaging device and experimental set up. Consult the manufacturer's manual for optimal results. 1. In the imaging software optimize exposure time, F/stop and pixel binning based on the expression level of the cell line. Change these settings at any time during an experiment without impacting the quantitative result. Alternatively, let the Imaging Wizard software automatically determine the parameters.
4. Image mice before injection and 6 hr after injection of antibody constructs. NOTE: The labelling efficacy may affect the required dose needed for optimal imaging results. Therefore the amount of required antibodyconstruct for optimal imaging results has to be determined empirically. It may vary depending on labelling efficacy and size of the construct as well as the tumor model and the target-antigen expression. BSA. 5. Add anti-CD45-mAb to discriminate leucocytes from other cells. Incubate for 20 min on ice in the dark, followed by two washes with PBS/0.2% BSA. 6. Right before FACS analysis stain with propidium iodide for 15 min on ice to discern dead cells, followed by two washes with plain PBS.
Harvesting and Preparation of Tumors
Resuspend in 150 µl for FACS analysis. NOTE: In step 3.7.4 and step 3.7.5 other antibodies may be used depending on the tumor entity.
FACS Analysis
1. Use a series of gating tools to gate the population of interest in the form of large scatter, doublet discrimination, exclusion of dead cells, gating for CD45 positive cells, and gating for antigen-positive cells. 1. At first, gate out cell debris in a forward scatter (FSC-A) versus side scatter (SSC-A) using a two-parameter plot. Next discard cell doublets. Finally, gate out non CD45-antigen-positive (CD45) and dead/dying cells (LD -live/dead-stain).
2. Record samples using the same template for all experiments. NOTE: Refer to the manufacturer's protocol for technical advice regarding the use of hardware and analytic software.
Microscopic Analysis
In Vivo Imaging Analysis
1. Open image files in imaging software and create an overlay image by combining photograph image data with fluorescence image data. Optimize image display by removing tissue autofluorescence background signal from the specific fluorescent signal. This can be done by subtracting the image acquired with a background filter set from the image acquired with the filter set specific for the tracer. 2. Draw identical circular measurement regions of interest (ROI) around the antigen-positive tumor and the antigen-negative tumor. To determine background signal intensity, place a circular ROI in an area of the animal where fluorescence signal is expected to be low (e.g., hind leg). 
Representative Results
Fluorescently labelled probes allow for the combination of different NIRF-imaging techniques ( Figure 1A) . We aimed to perform in vivo NIRFimaging, flow cytometry, and fluorescence microscopy sequentially in order to compare fluorescently labelled nanobodies and monoclonal antibodies for specific in vivo imaging ( Figure 1B ).
Mice were injected with 50 μg of nanobody and monoclonal antibody to evaluate the specificity of the fluorescently labelled constructs for in vivo imaging. The results showed specific labeling of antigen-positive tumors with both nanobody and monoclonal antibody at 6 hr after injection (Figure 2) . ROI analyses of the antigen-positive tumors showed a much higher T/B ratio of ~12 for the nanobody compared to ~6 for the monoclonal antibody. Moreover, the nanobody showed no nonspecific signal in the antigen-negative tumors, whereas the monoclonal antibody showed nonspecific confounding signals in the antigen-negative tumors.
Besides the nonspecific signal of the negative tumors, the monoclonal antibody also induced nonspecific background signals in the entire animal. This is likely due to excessive free circulating antibodies, which are too large to be renally excreted. Contrariwise, animals injected with nanobodies showed nonspecific signals only in the kidneys due to the renal elimination of the small nanobodies.
Flow cytometry analyses of tumor cell suspensions showed specific labeling of antigen-positive tumor cells with both AF680-conjugates 6 hr after injection. The stronger fluorescence signal of the nanobody labelled cells compared to monoclonal antibody labelled cells reflects the in vivo NIRF-imaging results. Importantly, the flow cytometric analyses reveal that there is no nonspecific labelling of antigen-negative cells with either of the two constructs (Figure 3) .
Fluorescence microscopy of tumor cryosections showed a strong and almost homogenous labeling of antigen-positive cells with the nanobody 6 hr after injection. Contrariwise, the monoclonal antibody showed a much weaker and rather inhomogeneous staining ( Figure 4A) . Antigennegative tumors show no staining 6 hr after injection of the nanobody, whereas antigen-negative tumors injected with the conventional antibody show nonspecific scattered staining in the interstitial space ( Figure 4B ).
Discussion
We used near-infrared fluorophore labelled nanobodies and conventional monoclonal antibodies directed against the same target on lymphoma cells for a multimodal comparison of in vivo and ex vivo analyses. We showed that nanobodies are well suited as diagnostic tools for rapid and specific in vivo detection of lymphomas.
In vivo, s+16a 680 allowed a fast and more specific detection of ARTC2-positive xenografts. Apart from the different kinetics for best tumor visualization in vivo, the major drawback of Nika102 680 was the high nonspecific signal from ARTC2-negative tumors and nonspecific background signals.
Ex vivo flow cytometric analyses of dispersed cells from dissected tumors showed no nonspecific binding to ARTC2-negative lymphoma cells of injected AF680-conjugates. Ex vivo fluorescence revealed strong and almost homogenous staining of cells in ART2C-positive tumor sections in case of nanobody s+16a, confirming that the nanobody was able to reach even remote areas within the tumor after 6 h. In contrast, the monoclonal antibody showed weaker and inhomogeneous staining of cells in ARTC2-positive tumors after 6 hr. Better imaging results with the conventional antibody can be achieved after 24 hr or 48 hr (data not shown). In order to perform a thorough comparison of two differently sized constructs, imaging at different time points (serial-imaging) has to be performed to identify the optimal imaging time point for each construct.
Like other previous studies, the results reported here emphasize that in vivo molecular imaging with labelled nanobodies allows rapid and specific same-day tumor imaging with high tumor-to-background ratios [12] [13] [14] [15] [17] [18] [19] . Contrariwise, conventional antibodies result in low tumor-tobackground ratios and nonspecific signals from antigen-negative tumors early after injection due to their slow clearance from the body. In order to obtain optimal imaging results with conventional antibodies, imaging time points 24 hr or even 48 hr after injection are commonly needed. These findings are in accord with previous studies that have suggested that conventional antibodies with proven therapeutic benefit have limited utility in molecular imaging 17, 19, 26 . Therefore conventional antibodies might be rather suited for therapeutic purposes due to their long plasma halflife while nanobodies are rather suited for imaging purposes due to their rapid clearance from the circulation. These differences are due to the fact that any excess of the smaller nanobodies (15-17 kDa) is rapidly cleared via renal elimination while excess of larger conventional antibodies (150 kDa) is retained in the circulation. So the major advantage of nanobodies for molecular imaging is the low background signal at early imaging time points regardless of the injected dose. This allows same day imaging and could be translatable to the clinical setting. Contrariwise, conventional antibodies have to be exactly titrated to minimize nonspecific background signals, while maintaining enough specific signal from the targeted tissue (unpublished data).
One of the limitations of the in vivo NIRF-imaging technique is the low penetration depth which generally allows only imaging of subcutaneous but not of orthotopic tumor models. However, this limitation might be overcome in an experimental setting by the recently developed tomographic photo-acoustic techniques that allow whole-body imaging of living mice 27 . Another limitation of the NIRF-imaging technique is the assessment of the tissue dose as compared to radionuclide-mediated imaging. However, the nanobodies may be radiolabelled for positron emission tomography (PET) imaging of xenograft models and exact quantitative assessment of tracer biodistribution. Indeed, our NIRF-imaging results are in accordance with a recent study that compared nanobodies and conventional antibodies for PET imaging. The authors also came to the conclusion that nanobodies allow same-day imaging with high tumor-to-background ratios 15 .
However, only the labelling of antibody constructs with the near-infrared fluorescent dye AF680 allowed us the comprehensive in vitro, in vivo and ex vivo near-infrared fluorescence imaging comparison using flow cytometry, fluorescence microscopy, and NIRF-imaging. For this reason, and because it is nonradioactive, highly sensitive, inexpensive, and uses comparatively easy-to-produce targeted probes, we advocate the use of the NIRF-imaging technique for evaluation of new antibody constructs in preclinical molecular imaging.
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